Le cluster Ruiyuan Cao - Zhihong Hu

Terms

2	Ruiyuan Cao
2	Zhihong Hu
2	Mingyue Xu
2	Manli Wang
3	Jia Liu
4	Wu Zhong
2	Pei Hao
2	Xuan Li

Associations

Freq.	Weight	Association
2	1.000	Ruiyuan Cao - Zhihong Hu
2	1.000	Mingyue Xu - Zhihong Hu
2	1.000	Mingyue Xu - Ruiyuan Cao
2	1.000	Manli Wang - Zhihong Hu
2	1.000	Manli Wang - Ruiyuan Cao
2	1.000	Manli Wang - Mingyue Xu
2	0.816	Jia Liu - Zhihong Hu
2	0.816	Jia Liu - Ruiyuan Cao
2	0.816	Jia Liu - Mingyue Xu
2	0.816	Jia Liu - Manli Wang
2	0.707	Wu Zhong - Zhihong Hu
2	0.707	Wu Zhong - Xuan Li
2	1.000	Pei Hao - Xuan Li
2	0.707	Ruiyuan Cao - Wu Zhong
2	0.707	Pei Hao - Wu Zhong
2	0.707	Mingyue Xu - Wu Zhong
2	0.707	Manli Wang - Wu Zhong
2	0.577	Jia Liu - Wu Zhong

Documents par ordre de pertinence

000194 (2020)	Manli Wang [République populaire de Chine] ; Ruiyuan Cao [République populaire de Chine] ; Leike Zhang [République populaire de Chine] ; Xinglou Yang [République populaire de Chine] ; Jia Liu [République populaire de Chine] ; Mingyue Xu [République populaire de Chine] ; Zhengli Shi [République populaire de Chine] ; Zhihong Hu [République populaire de Chine] ; Wu Zhong [République populaire de Chine] ; Gengfu Xiao [République populaire de Chine]	Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
000354 (2020)	Jia Liu [République populaire de Chine] ; Ruiyuan Cao [République populaire de Chine] ; Mingyue Xu [République populaire de Chine] ; Xi Wang [République populaire de Chine] ; Huanyu Zhang [République populaire de Chine] ; Hengrui Hu [République populaire de Chine] ; Yufeng Li [République populaire de Chine] ; Zhihong Hu [République populaire de Chine] ; Wu Zhong [République populaire de Chine] ; Manli Wang [République populaire de Chine]	Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro
000325 (2020)	Pei Hao [République populaire de Chine] ; Wu Zhong [République populaire de Chine] ; Shiyang Song [République populaire de Chine] ; Shiyong Fan [République populaire de Chine] ; Xuan Li [République populaire de Chine]	Is SARS-CoV-2 originated from laboratory? A rebuttal to the claim of formation via laboratory recombination.
000395 (2020)	Xintian Xu [République populaire de Chine] ; Ping Chen [République populaire de Chine] ; Jingfang Wang [République populaire de Chine] ; Jiannan Feng [République populaire de Chine] ; Hui Zhou [République populaire de Chine] ; Xuan Li [République populaire de Chine] ; Wu Zhong [République populaire de Chine] ; Pei Hao [République populaire de Chine]	Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission
000263 (2020)	Jia Liu [République populaire de Chine] ; Xin Zheng [République populaire de Chine] ; Qiaoxia Tong [République populaire de Chine] ; Wei Li [République populaire de Chine] ; Baoju Wang [République populaire de Chine] ; Kathrin Sutter [Allemagne] ; Mirko Trilling [Allemagne] ; Mengji Lu [Allemagne] ; Ulf Dittmer [Allemagne] ; Dongliang Yang [République populaire de Chine]	Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV.

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Sat Mar 28 17:51:24 2020. Site generation: Sun Jan 31 15:35:48 2021